Ghia P, Pluta A, Wach M, et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 24th Congress of EHA, abstract LB2606.
Anakinra vermindert gebruik van antibiotica bij hematologische maligniteit
mei 2022 | Antibioticaresistentie, Leukemie, Lymfoom, MM